期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 63, 期 21, 页码 12773-12785出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c01107
关键词
-
资金
- Australian National Health & Medical Research Council [APP1072113, APP1136889]
- University of Queensland (UQ Postdoctoral Fellowship)
- European Research Council under the European Union's Horizon 2020 research and innovation program [714366]
- Australian Research Council [DP190101667]
Voltage-gated sodium (NaV) channels are pore-forming transmembrane proteins that play essential roles in excitable cells, and they are key targets for antiepileptic, antiarrhythmic, and analgesic drugs. We implemented a heterobivalent design strategy to modulate the potency, selectivity, and binding kinetics of Na-V channel ligands. We conjugated mu-conotoxin KIIIA, which occludes the pore of the Na-V channels, to an analogue of huwentoxin-IV, a spider-venom peptide that allosterically modulates channel gating. Bioorthogonal hydrazide and copper-assisted azide-alkyne cycloaddition conjugation chemistries were employed to generate heterobivalent ligands using polyethylene glycol linkers spanning 40-120 angstrom. The ligand with an 80 angstrom linker had the most pronounced bivalent effects, with a significantly slower dissociation rate and 4-24-fold higher potency compared to those of the monovalent peptides for the human Na(V)1.4 channel. This study highlights the power of heterobivalent ligand design and expands the repertoire of pharmacological probes for exploring the function of Na-V channels.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据